Profound Medical Corp.

Toronto Stock Exchange PRN.TO

Profound Medical Corp. EPS (Diluted) for the year ending December 31, 2023: USD -1.35

Profound Medical Corp. EPS (Diluted) is USD -1.35 for the year ending December 31, 2023, a 2.17% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Profound Medical Corp. EPS (Diluted) for the year ending December 31, 2022 was USD -1.38, a 8.00% change year over year.
Profound Medical Corp. EPS (Diluted) for the year ending December 31, 2021 was USD -1.50, a -20.00% change year over year.
Profound Medical Corp. EPS (Diluted) for the year ending December 31, 2020 was USD -1.25, a -16.88% change year over year.
Profound Medical Corp. EPS (Diluted) for the year ending December 31, 2019 was USD -1.07, a 3.99% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

Toronto Stock Exchange: PRN.TO

Profound Medical Corp.

CEO	Dr. Arun Swarup Menawat MBA, Ph.D.
IPO Date	July 10, 2018
Location	Canada
Headquarters	2400 Skymark Avenue
Employees	131
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Clinical Trials Dental Care Drugstores & Retail Pharmacies Pharmaceuticals Telehealth

Description

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Key trends

Past 5 years